Pharmacokinetic, pharmacodynamic, and transcriptomic analysis of chronic levetiracetam treatment in 5XFAD mice: A MODEL‐AD preclinical testing core study

Pharmacokinetic, pharmacodynamic, and transcriptomic analysis of chronic levetiracetam treatment in 5XFAD mice: A MODEL‐AD preclinical testing core study

Abstract Introduction Hyperexcitability and epileptiform activity are commonplace in Alzheimer's disease (AD) patients and associated with impaired cognitive function. The anti‐seizure drug levetiracetam (LEV) is currently being evaluated in clinical trials for ability to reduce epileptiform ac...

Full description

Bibliographic Details
Main Authors: Kristen D. Onos, Sara K. Quinney, David R. Jones, Andrea R. Masters, Ravi Pandey, Kelly J. Keezer, Carla Biesdorf, Ingrid F. Metzger, Jill A. Meyers, Johnathon Peters, Scott C. Persohn, Brian P. McCarthy, Amanda A. Bedwell, Lucas L. Figueiredo, Zackary A. Cope, Michael Sasner, Gareth R. Howell, Harriet M. Williams, Adrian L. Oblak, Bruce T. Lamb, Gregory W. Carter, Stacey J. Sukoff Rizzo, Paul R. Territo
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Subjects:
Alzheimer's disease
levetiracetam
preclinical testing
5XFAD
Online Access:https://doi.org/10.1002/trc2.12329

Similar Items

Similar Items